Developing Breakthrough Treatments for Invasive Lobular Carcinoma
from Breast Cancer Trials Hosted by Breast Cancer Trials
Developing Breakthrough Treatments for Invasive Lobular Carcinoma Invasive Lobular Carcinoma (ILC) is the second most common subtype of breast cancer, with 2,400 new cases each year in Australia. Patients with ILC may have a poorer outcome over time and the cancer has a tendency to metastasize to atypical sites such as the gastrointestinal tract, gynaecological organs or orbit (eye). We spoke with Dr Sokolova about her research project, which will examine a new treatment approach directed at ILC. Like this episode? Follow Breast Cancer Trials on Social Media: Instagram: @breastcancertrials Facebook: Breast Cancer Trials LinkedIn: Breast Cancer Trials X: @BCTrialsANZ Guest: Dr Anna Sokolova Thank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about clinical trials research. Find out more: www.breastcancertrials.org.au
Embed this episode
No transcript yet.